Toleranzia Past Earnings Performance
Past criteria checks 0/6
Toleranzia's earnings have been declining at an average annual rate of -7.4%, while the Biotechs industry saw earnings declining at 1.4% annually. Revenues have been growing at an average rate of 43.9% per year.
Key information
-7.4%
Earnings growth rate
45.0%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 43.9% |
| Return on equity | -4.9% |
| Net Margin | -14.5% |
| Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Toleranzia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 51 | -7 | 6 | 0 |
| 30 Sep 23 | 53 | -8 | 44 | 0 |
| 30 Jun 23 | 46 | -9 | 44 | 0 |
| 31 Mar 23 | 37 | -8 | 46 | 0 |
| 31 Dec 22 | 35 | -8 | 44 | 0 |
| 30 Sep 22 | 28 | -8 | 11 | 0 |
| 30 Jun 22 | 33 | -8 | 19 | 0 |
| 31 Mar 22 | 29 | -7 | 36 | 0 |
| 31 Dec 21 | 28 | -6 | 34 | 0 |
| 30 Sep 21 | 26 | -6 | 42 | 0 |
| 30 Jun 21 | 20 | -6 | 34 | 0 |
| 31 Mar 21 | 18 | -5 | 25 | 0 |
| 31 Dec 20 | 13 | -5 | 18 | 0 |
| 30 Sep 20 | 12 | -7 | 4 | 0 |
| 30 Jun 20 | 12 | -7 | 4 | 0 |
| 31 Mar 20 | 8 | -8 | 4 | 0 |
| 31 Dec 19 | 7 | -8 | 4 | 0 |
| 30 Sep 19 | 5 | -6 | 4 | 0 |
| 30 Jun 19 | 5 | -5 | 4 | 0 |
| 31 Mar 19 | 4 | -5 | 4 | 0 |
| 31 Dec 18 | 4 | -6 | 4 | 0 |
| 30 Sep 18 | 4 | -6 | 4 | 0 |
| 30 Jun 18 | 3 | -5 | 4 | 0 |
| 31 Mar 18 | 3 | -6 | 4 | 0 |
| 31 Dec 17 | 3 | -5 | 4 | 0 |
| 30 Sep 17 | 2 | -6 | 3 | 0 |
| 30 Jun 17 | 3 | -6 | 3 | 0 |
| 31 Mar 17 | 3 | -5 | 3 | 0 |
| 31 Dec 16 | 4 | -5 | 3 | 0 |
| 30 Sep 16 | 4 | -6 | 3 | 0 |
| 30 Jun 16 | 3 | -6 | 3 | 0 |
| 31 Mar 16 | 3 | -5 | 2 | 0 |
| 31 Dec 15 | 2 | -4 | 2 | 0 |
| 31 Dec 14 | 2 | -1 | 2 | 0 |
| 31 Dec 13 | 3 | 0 | 1 | 0 |
Quality Earnings: TOL is currently unprofitable.
Growing Profit Margin: TOL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TOL is unprofitable, and losses have increased over the past 5 years at a rate of 7.4% per year.
Accelerating Growth: Unable to compare TOL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TOL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: TOL has a negative Return on Equity (-4.86%), as it is currently unprofitable.